RHYTHM PHARMACEUTICALS, INC. Basic Shares Outstanding (Weighted Average)
RHYTHM PHARMACEUTICALS, INC. (RYTM) reported Basic Shares Outstanding (Weighted Average) of 68.59 million shares for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:WeightedAverageNumberOfSharesOutstandingBasic · last filed 2026-08-04
- RHYTHM PHARMACEUTICALS, INC. weighted average number of shares outstanding, basic for the quarter ending 2026-06-30 was 68.59M shares, a 7.71% increase year-over-year.
- RHYTHM PHARMACEUTICALS, INC. weighted average number of shares outstanding, basic for the quarter ending 2026-03-31 was 67.97M shares, a 7.79% increase year-over-year.
- RHYTHM PHARMACEUTICALS, INC. weighted average number of shares outstanding, basic for the quarter ending 2025-12-31 was 66.90M shares, a 8.60% increase year-over-year.
- RHYTHM PHARMACEUTICALS, INC. weighted average number of shares outstanding, basic for the quarter ending 2025-09-30 was 66.26M shares, a 8.23% increase year-over-year.
- RHYTHM PHARMACEUTICALS, INC. weighted average number of shares outstanding, basic for fiscal 2025 was 64.98M shares, a 6.54% increase from fiscal 2024.
- RHYTHM PHARMACEUTICALS, INC. weighted average number of shares outstanding, basic for fiscal 2024 was 61.00M shares, a 5.76% increase from fiscal 2023.
- RHYTHM PHARMACEUTICALS, INC. weighted average number of shares outstanding, basic for fiscal 2023 was 57.67M shares, a 10.65% increase from fiscal 2022.
- RHYTHM PHARMACEUTICALS, INC. weighted average number of shares outstanding, basic for fiscal 2022 was 52.12M shares, a 5.08% increase from fiscal 2021.
| Period end | Weighted Average Number of Shares Outstanding, Basic 3 month | Weighted Average Number of Shares Outstanding, Basic 6 month | Weighted Average Number of Shares Outstanding, Basic 9 month | Weighted Average Number of Shares Outstanding, Basic 12 month |
|---|---|---|---|---|
| 2026-06-30 | 68.59M shares 10-Q · filed 2026-08-04 | 68.29M shares 10-Q · filed 2026-08-04 | 67.82M shares derived: average of 3 quarters · filed 2026-08-04 | 67.43M shares derived: average of 4 quarters · filed 2026-08-04 |
| 2026-03-31 | 67.97M shares 10-Q · filed 2026-05-05 | 67.44M shares derived: average of 2 quarters · filed 2026-05-05 | 67.04M shares derived: average of 3 quarters · filed 2026-05-05 | 66.20M shares derived: average of 4 quarters · filed 2026-08-04 |
| 2025-12-31 | 66.90M shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | 66.58M shares derived: average of 2 quarters · filed 2026-02-26 | 65.61M shares derived: average of 3 quarters · filed 2026-08-04 | 64.98M shares 10-K · filed 2026-02-26 |
| 2025-09-30 | 66.26M shares 10-Q · filed 2025-11-04 | 64.97M shares derived: average of 2 quarters · filed 2026-08-04 | 64.35M shares 10-Q · filed 2025-11-04 | 63.65M shares derived: average of 4 quarters · filed 2026-08-04 |
| 2025-06-30 | 63.68M shares 10-Q · filed 2026-08-04 | 63.37M shares 10-Q · filed 2026-08-04 | 62.78M shares derived: average of 3 quarters · filed 2026-08-04 | 62.39M shares derived: average of 4 quarters · filed 2026-08-04 |
| 2025-03-31 | 63.06M shares 10-Q · filed 2026-05-05 | 62.33M shares derived: average of 2 quarters · filed 2026-05-05 | 61.96M shares derived: average of 3 quarters · filed 2026-05-05 | 61.72M shares derived: average of 4 quarters · filed 2026-05-05 |
| 2024-12-31 | 61.60M shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | 61.41M shares derived: average of 2 quarters · filed 2026-02-26 | 61.28M shares derived: average of 3 quarters · filed 2026-02-26 | 61.00M shares 10-K · filed 2026-02-26 |
| 2024-09-30 | 61.22M shares 10-Q · filed 2025-11-04 | 61.12M shares derived: average of 2 quarters · filed 2025-11-04 | 60.79M shares 10-Q · filed 2025-11-04 | 60.40M shares derived: average of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | 61.01M shares 10-Q · filed 2025-08-05 | 60.58M shares 10-Q · filed 2025-08-05 | 60.13M shares derived: average of 3 quarters · filed 2026-02-26 | 59.56M shares derived: average of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | 60.14M shares 10-Q · filed 2025-05-07 | 59.69M shares derived: average of 2 quarters · filed 2026-02-26 | 59.08M shares derived: average of 3 quarters · filed 2026-02-26 | 58.53M shares derived: average of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | 59.23M shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | 58.55M shares derived: average of 2 quarters · filed 2026-02-26 | 57.99M shares derived: average of 3 quarters · filed 2026-02-26 | 57.67M shares 10-K · filed 2026-02-26 |
| 2023-09-30 | 57.87M shares 10-Q · filed 2024-11-06 | 57.37M shares derived: average of 2 quarters · filed 2024-11-06 | 57.15M shares 10-Q · filed 2024-11-06 | 56.95M shares derived: average of 4 quarters · filed 2025-02-28 |
| 2023-06-30 | 56.87M shares 10-Q · filed 2024-08-06 | 56.79M shares 10-Q · filed 2024-08-06 | 56.64M shares derived: average of 3 quarters · filed 2025-02-28 | 55.33M shares derived: average of 4 quarters · filed 2025-02-28 |
| 2023-03-31 | 56.71M shares 10-Q · filed 2024-05-07 | 56.53M shares derived: average of 2 quarters · filed 2025-02-28 | 54.82M shares derived: average of 3 quarters · filed 2025-02-28 | 53.71M shares derived: average of 4 quarters · filed 2025-02-28 |
| 2022-12-31 | 56.35M shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-28 | 53.87M shares derived: average of 2 quarters · filed 2025-02-28 | 52.71M shares derived: average of 3 quarters · filed 2025-02-28 | 52.12M shares 10-K · filed 2025-02-28 |
| 2022-09-30 | 51.40M shares 10-Q · filed 2023-11-08 | 50.90M shares derived: average of 2 quarters · filed 2023-11-08 | 50.71M shares 10-Q · filed 2023-11-08 | 50.60M shares derived: average of 4 quarters · filed 2024-02-29 |
| 2022-06-30 | 50.40M shares 10-Q · filed 2023-08-01 | 50.36M shares 10-Q · filed 2023-08-01 | 50.33M shares derived: average of 3 quarters · filed 2024-02-29 | 50.31M shares derived: average of 4 quarters · filed 2024-02-29 |
| 2022-03-31 | 50.33M shares 10-Q · filed 2023-05-02 | 50.30M shares derived: average of 2 quarters · filed 2024-02-29 | 50.28M shares derived: average of 3 quarters · filed 2024-02-29 | 50.27M shares derived: average of 4 quarters · filed 2024-02-29 |
| 2021-12-31 | 50.28M shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | 50.26M shares derived: average of 2 quarters · filed 2024-02-29 | 50.24M shares derived: average of 3 quarters · filed 2024-02-29 | 49.60M shares 10-K · filed 2024-02-29 |
| 2021-09-30 | 50.25M shares 10-Q · filed 2022-11-08 | 50.23M shares derived: average of 2 quarters · filed 2022-11-08 | 49.37M shares 10-Q · filed 2022-11-08 | |
| 2021-06-30 | 50.21M shares 10-Q · filed 2022-08-03 | 48.93M shares 10-Q · filed 2022-08-03 | ||
| 2021-03-31 | 47.64M shares 10-Q · filed 2022-05-03 | |||
| 2020-12-31 | 44.13M shares 10-K · filed 2023-03-01 | |||
| 2020-06-30 | 44.10M shares 10-Q · filed 2021-08-03 | 44.07M shares 10-Q · filed 2021-08-03 | ||
| 2020-03-31 | 44.05M shares 10-Q · filed 2021-05-03 | |||
| 2019-12-31 | 36.42M shares 10-K · filed 2022-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |